Vivos Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
3analysts covering
FY Revenue (est.)
$24.1Mnext fiscal year
FY EPS (est.)
-$1.39next fiscal year
Monitoring Framework
Key Performance Indicators
Oral Appliance Unit Sales Quarterly5.3K
Quarterly Revenue Quarterly5.1M
Gross Margin Quarterly60.0%
Watch Items
- Nasdaq Minimum Stockholders' Equity Requirement ComplianceTrigger: Below $2.5 million in stockholders' equityAction: Execute equity financings, debt-to-equity exchanges, or rights offerings to restore positive equity balance.
- Nasdaq Minimum Bid Price ComplianceTrigger: Closing bid price below $1.00 for 30 consecutive business daysAction: Monitor stock price and evaluate potential reverse stock split or organic recovery strategies.
- Cash Burn Rate and Going Concern StatusTrigger: Cash reserves insufficient to fund 12 months of operationsAction: Secure additional dilutive or non-dilutive financing to support operational expansion.
Research as of 20 Jun 2026